Amgen (AMGN.US) has obtained commercial rights for Evolocumab in Asia and other areas and has applied for listing in China.

On July 3rd, Amgen (AMGN.US) announced that it has reached an agreement with CSL Vifor to acquire commercial rights to Evolocumab in Asia and the Americas, including mainland China.

Zhitong Finance14:32

NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss

Yahoo Finance20:19

Amgen Inc. (NASDAQ:AMGN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Yahoo Finance19:00

S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?

The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ

Benzinga01:04

Express News | Amgen received commercialization rights for Avacopan in Asia and the Americas.

BreakingsJul 3 15:40

What the Options Market Tells Us About Amgen

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.Delving into the details, we found 11% of traders were

BenzingaJul 3 04:01